NASDAQ: AKTXAkari Therapeutics PLC Stock
$7.54+0.54 (+7.71%)
Updated Aug 14, 2026
AKTX Price
$7.54
Fair Value Price
N/A
Market Cap
$0.00
52 Week Low
$3.02
52 Week High
$49.60
P/E
N/A
P/B
0x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$30.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.08
Operating Cash Flow
-$11M
Beta
0.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AKTX Overview
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AKTX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
AKTX
Ranked#436 of 461
Ranked#436 of 461
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.83 | A | |
| $114.47 | A | |
| $347.48 | A |
Be the first to know about important AKTX news, forecast changes, insider trades & much more!
AKTX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AKTX's cash burn is expected to be positive in the next year ($2.94M), after accounting for decreasing cash burn (72.66%)
Interest Coverage Financials
AKTX's short-term liabilities ($13.94M) exceed its short-term assets ($8.32M)
Short-term Liabilities Financials
AKTX's short-term assets ($8.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more AKTX due diligence checks available for Premium users.
Valuation
AKTX fair value
Fair Value of AKTX stock based on Discounted Cash Flow (DCF)
Price
$7.54
Fair Value
$5.29
Overvalued by
42.63%
AKTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0x
Industry
5.62x
AKTX's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.8M
Profit Margin
0%
AKTX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$38.6M
Liabilities
$20.0M
Debt to equity
1.08
AKTX's short-term liabilities ($13.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's short-term assets ($8.32M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
$0.0
Financing
$8.0M
AKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AKTX vs Biotech Stocks
Akari Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.